The FDA approved AbbVie’s next-generation dopamine agonist tavapadon for Parkinson’s disease, to be marketed as Juvmo. The company positions the therapy as an improvement over existing dopamine agonists, aiming to deliver symptom relief with fewer side effects—highlighting a continuing push for incremental advances in chronic neurodegenerative care.